Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 103

Similar articles for PubMed (Select 21945306)

1.

Neurobiological elements of cognitive dysfunction in down syndrome: exploring the role of APP.

Millan Sanchez M, Heyn SN, Das D, Moghadam S, Martin KJ, Salehi A.

Biol Psychiatry. 2012 Mar 1;71(5):403-9. doi: 10.1016/j.biopsych.2011.08.016. Epub 2011 Sep 25. Review.

PMID:
21945306
2.

Down syndrome and Alzheimer's disease: Common pathways, common goals.

Hartley D, Blumenthal T, Carrillo M, DiPaolo G, Esralew L, Gardiner K, Granholm AC, Iqbal K, Krams M, Lemere C, Lott I, Mobley W, Ness S, Nixon R, Potter H, Reeves R, Sabbagh M, Silverman W, Tycko B, Whitten M, Wisniewski T.

Alzheimers Dement. 2015 Jun;11(6):700-9. doi: 10.1016/j.jalz.2014.10.007. Epub 2014 Dec 12.

PMID:
25510383
3.

Long-term effects of neonatal treatment with fluoxetine on cognitive performance in Ts65Dn mice.

Stagni F, Giacomini A, Guidi S, Ciani E, Ragazzi E, Filonzi M, De Iasio R, Rimondini R, Bartesaghi R.

Neurobiol Dis. 2015 Feb;74:204-18. doi: 10.1016/j.nbd.2014.12.005. Epub 2014 Dec 10.

PMID:
25497735
4.

Expression profile analysis of vulnerable CA1 pyramidal neurons in young-Middle-Aged Ts65Dn mice.

Alldred MJ, Lee SH, Petkova E, Ginsberg SD.

J Comp Neurol. 2015 Jan 1;523(1):61-74. doi: 10.1002/cne.23663. Epub 2014 Aug 30.

PMID:
25131634
5.

Expression profile analysis of hippocampal CA1 pyramidal neurons in aged Ts65Dn mice, a model of Down syndrome (DS) and Alzheimer's disease (AD).

Alldred MJ, Lee SH, Petkova E, Ginsberg SD.

Brain Struct Funct. 2014 Jul 17. [Epub ahead of print]

PMID:
25031177
6.

Neurotransmitter-based strategies for the treatment of cognitive dysfunction in Down syndrome.

Das D, Phillips C, Hsieh W, Sumanth K, Dang V, Salehi A.

Prog Neuropsychopharmacol Biol Psychiatry. 2014 Oct 3;54:140-8. doi: 10.1016/j.pnpbp.2014.05.004. Epub 2014 May 17. Review.

PMID:
24842803
7.

APP-dependent alteration of GSK3β activity impairs neurogenesis in the Ts65Dn mouse model of Down syndrome.

Trazzi S, Fuchs C, De Franceschi M, Mitrugno VM, Bartesaghi R, Ciani E.

Neurobiol Dis. 2014 Jul;67:24-36. doi: 10.1016/j.nbd.2014.03.003. Epub 2014 Mar 15.

PMID:
24636797
8.

Dosage of amyloid precursor protein affects axonal contact guidance in Down syndrome.

Sosa LJ, Postma NL, Estrada-Bernal A, Hanna M, Guo R, Busciglio J, Pfenninger KH.

FASEB J. 2014 Jan;28(1):195-205. doi: 10.1096/fj.13-232686. Epub 2013 Sep 13.

9.
10.

Aging and intellectual disability: insights from mouse models of Down syndrome.

Ruparelia A, Pearn ML, Mobley WC.

Dev Disabil Res Rev. 2013;18(1):43-50. doi: 10.1002/ddrr.1127. Review.

PMID:
23949828
11.

Prospects for improving brain function in individuals with Down syndrome.

Costa AC, Scott-McKean JJ.

CNS Drugs. 2013 Sep;27(9):679-702. doi: 10.1007/s40263-013-0089-3. Review.

PMID:
23821040
12.

Noradrenergic modulation of cognition: therapeutic implications.

Chamberlain SR, Robbins TW.

J Psychopharmacol. 2013 Aug;27(8):694-718. doi: 10.1177/0269881113480988. Epub 2013 Mar 21. Review. Erratum in: J Psychopharmacol. 2013 Oct;27(10):964.

PMID:
23518815
13.

New therapies for treating Down syndrome require quality of life measurement.

Goodman MJ, Brixner DI.

Am J Med Genet A. 2013 Apr;161A(4):639-41. doi: 10.1002/ajmg.a.35705. Epub 2013 Mar 12. Review.

PMID:
23495233
14.

Cognitive enhancement by pharmacological and behavioral interventions: the murine Down syndrome model.

Möhler H.

Biochem Pharmacol. 2012 Oct 15;84(8):994-9. doi: 10.1016/j.bcp.2012.06.028. Epub 2012 Aug 8.

PMID:
22898099
15.

Molecular and cellular alterations in Down syndrome: toward the identification of targets for therapeutics.

Créau N.

Neural Plast. 2012;2012:171639. doi: 10.1155/2012/171639. Epub 2012 Jul 12. Review.

16.

From abnormal hippocampal synaptic plasticity in down syndrome mouse models to cognitive disability in down syndrome.

Cramer N, Galdzicki Z.

Neural Plast. 2012;2012:101542. doi: 10.1155/2012/101542. Epub 2012 Jul 12. Review.

17.

Modulating cognitive deficits and tau accumulation in a mouse model of aging Down syndrome through neonatal implantation of neural progenitor cells.

Rachubinski AL, Maclean KN, Evans JR, Bjugstad KB.

Exp Gerontol. 2012 Sep;47(9):723-33. doi: 10.1016/j.exger.2012.06.013. Epub 2012 Jul 7.

PMID:
22776132
18.

Mouse models of Down syndrome as a tool to unravel the causes of mental disabilities.

Rueda N, Flórez J, Martínez-Cué C.

Neural Plast. 2012;2012:584071. doi: 10.1155/2012/584071. Epub 2012 May 22. Review.

19.

Cognitive and pharmacological insights from the Ts65Dn mouse model of Down syndrome.

Ruparelia A, Pearn ML, Mobley WC.

Curr Opin Neurobiol. 2012 Oct;22(5):880-6. doi: 10.1016/j.conb.2012.05.002. Epub 2012 May 30.

20.

Age-related neurodegeneration and memory loss in down syndrome.

Lockrow JP, Fortress AM, Granholm AC.

Curr Gerontol Geriatr Res. 2012;2012:463909. doi: 10.1155/2012/463909. Epub 2012 Mar 20.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk